Exenatide once weekly slows gastric emptying of solids and liquids in healthy, overweight people at steady-state concentrations.

Jones KL, Huynh LQ, Hatzinikolas S, Rigda RS, Phillips LK, Pham HT, Marathe CS, Wu T, Malbert CH, Stevens JE, Lange K, Rayner CK, Horowitz M

Diabetes, obesity & metabolism28 Jan 2020Cited by 59 (Europe PMC)

PMID31903712DOI10.1111/dom.13956PepBankPUB-31903712

Publisher page PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialSafety outcome
In healthy overweight participants, exenatide and placebo were well tolerated.
In plain wordsIn healthy overweight participants, exenatide and placebo were well tolerated.
Peptide
Exenatide (exendin-4)
Outcome
Not applicableOverall tolerability
Study
n = 32
Comparator
Matching placebo
Outcome group
Adverse events · Whole body
Studied dose
2 mg/wk · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
The study treatments were well tolerated.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 32 healthy participants were randomized to receive either EXE once weekly (2 mg/wk subcutaneously; six men, 10 women, mean age 59.9 ± 0.9 years, mean body mass index [BMI] 29.6 ± 0.6 kg/m² ) or matching placebo (PBO; six men, 10 women, mean age 60.6 ± 1.2 years, mean BMI 29.5 ±…
Report a problemFND-3190371201
02HumanRandomized controlled trialSafety outcome
In healthy overweight participants, nausea scores were low and did not differ between exenatide and placebo.
In plain wordsIn healthy overweight participants, nausea scores were low and did not differ between exenatide and placebo.
Peptide
Exenatide (exendin-4)
Outcome
No significant changeNausea score
Study
n = 32
Comparator
Matching placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
2 mg/wk · subcutaneous · 8 weeksAs given in this study (human).
Source sentences
Summary
Scores for nausea were consistently low, with no difference between the EXE once weekly and PBO groups.
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 32 healthy participants were randomized to receive either EXE once weekly (2 mg/wk subcutaneously; six men, 10 women, mean age 59.9 ± 0.9 years, mean body mass index [BMI] 29.6 ± 0.6 kg/m² ) or matching placebo (PBO; six men, 10 women, mean age 60.6 ± 1.2 years, mean BMI 29.5 ±…
Report a problemFND-3190371202
03HumanRandomized controlled trialEfficacy outcome
In healthy overweight participants, exenatide slowed gastric emptying of solids compared with placebo.
In plain wordsIn healthy overweight participants, exenatide slowed solid food leaving the stomach compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGastric emptying of solids
Study
n = 32
Comparator
Matching placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
2 mg/wk · subcutaneous · 8 weeksAs given in this study (human).
Measurements
P value, AUC 0-120 min
< 0.05 P
gastric emptying of solids
Source sentences
Summary
EXE once weekly slowed gastric emptying of solids (area under the curve [AUC]_0-120min : P 0-120min : P = 0.01) substantially,
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 32 healthy participants were randomized to receive either EXE once weekly (2 mg/wk subcutaneously; six men, 10 women, mean age 59.9 ± 0.9 years, mean body mass index [BMI] 29.6 ± 0.6 kg/m² ) or matching placebo (PBO; six men, 10 women, mean age 60.6 ± 1.2 years, mean BMI 29.5 ±…
Report a problemFND-3190371203
04HumanRandomized controlled trialEfficacy outcome
In healthy overweight participants, exenatide slowed gastric emptying of liquids compared with placebo.
In plain wordsIn healthy overweight participants, exenatide slowed liquids leaving the stomach compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGastric emptying of liquids
Study
n = 32
Comparator
Matching placebo
Outcome group
Gastrointestinal motility · Gastrointestinal
Studied dose
2 mg/wk · subcutaneous · 8 weeksAs given in this study (human).
Measurements
P value, AUC 0-120 min
0.01 P
gastric emptying of liquids
Source sentences
Summary
EXE once weekly slowed gastric emptying of solids (area under the curve [AUC]_0-120min : P 0-120min : P = 0.01) substantially,
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 32 healthy participants were randomized to receive either EXE once weekly (2 mg/wk subcutaneously; six men, 10 women, mean age 59.9 ± 0.9 years, mean body mass index [BMI] 29.6 ± 0.6 kg/m² ) or matching placebo (PBO; six men, 10 women, mean age 60.6 ± 1.2 years, mean BMI 29.5 ±…
Report a problemFND-3190371204
05HumanRandomized controlled trialEfficacy outcome
In healthy overweight participants, exenatide attenuated glucose absorption compared with placebo.
In plain wordsIn healthy overweight participants, exenatide reduced glucose absorption compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose absorption
Study
n = 32
Comparator
Matching placebo
Outcome group
Glycemic control · Gastrointestinal
Studied dose
2 mg/wk · subcutaneous · 8 weeksAs given in this study (human).
Measurements
P value, 3-OMG iAUC 0-30 min
0.001 P
glucose absorption
Source sentences
Summary
and attenuated glucose absorption (3-OMG incremental AUC [iAUC]_0-30min : P = 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 32 healthy participants were randomized to receive either EXE once weekly (2 mg/wk subcutaneously; six men, 10 women, mean age 59.9 ± 0.9 years, mean body mass index [BMI] 29.6 ± 0.6 kg/m² ) or matching placebo (PBO; six men, 10 women, mean age 60.6 ± 1.2 years, mean BMI 29.5 ±…
Report a problemFND-3190371205
06HumanRandomized controlled trialEfficacy outcome
In healthy overweight participants, exenatide attenuated the postprandial plasma glucose rise compared with placebo.
In plain wordsIn healthy overweight participants, exenatide reduced the blood sugar rise after a meal compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial glucose rise
Study
n = 32
Comparator
Matching placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg/wk · subcutaneous · 8 weeksAs given in this study (human).
Measurements
P value, glucose iAUC 0-30 min
0.008 P
postprandial plasma glucose
Source sentences
Summary
and the postprandial rise in plasma glucose (iAUC_0-30min : P = 0.008).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 32 healthy participants were randomized to receive either EXE once weekly (2 mg/wk subcutaneously; six men, 10 women, mean age 59.9 ± 0.9 years, mean body mass index [BMI] 29.6 ± 0.6 kg/m² ) or matching placebo (PBO; six men, 10 women, mean age 60.6 ± 1.2 years, mean BMI 29.5 ±…
Report a problemFND-3190371206
07HumanRandomized controlled trialMechanism
In healthy overweight participants, exenatide reduced plasma glucagon at 2 hours compared with placebo.
In plain wordsIn healthy overweight participants, exenatide reduced glucagon after a meal compared with placebo.
Peptide
Exenatide (exendin-4)
Outcome
DecreasePostprandial glucagon
Study
n = 32
Comparator
Matching placebo
Outcome group
Glycemic control · Endocrine and hormones
Studied dose
2 mg/wk · subcutaneous · 8 weeksAs given in this study (human).
Measurements
P value
0.001 P
plasma glucagon at 2 h
Source sentences
Summary
Plasma glucagon at 2 h was reduced by EXE once weekly (P = 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 32 healthy participants were randomized to receive either EXE once weekly (2 mg/wk subcutaneously; six men, 10 women, mean age 59.9 ± 0.9 years, mean body mass index [BMI] 29.6 ± 0.6 kg/m² ) or matching placebo (PBO; six men, 10 women, mean age 60.6 ± 1.2 years, mean BMI 29.5 ±…
Report a problemFND-3190371207
08HumanRandomized controlled trialMechanism
In exenatide-treated participants, glucose reduction magnitude correlated inversely with the glucose drink half-emptying time.
In plain wordsIn exenatide-treated participants, the size of the glucose reduction was inversely linked to the drink's stomach emptying time.
Peptide
Exenatide (exendin-4)
Outcome
DecreaseGlucose reduction association with gastric emptying
Study
n = 16
Outcome group
Glycemic control · Metabolic and weight
Studied dose
2 mg/wk · subcutaneous · 8 weeksAs given in this study (human).
Measurements
Correlation coefficient r
−0.55 r
glucose reduction at 30 min versus 50% emptying time of glucose drink, exenatide group
P value
0.03 P
correlation
Source sentences
Summary
The magnitude of the reduction in plasma glucose at t = 30 min from baseline to 8 weeks with EXE once weekly was related inversely to the 50% emptying time of the glucose drink (r = -0.55, P = 0.03).
1 context sentence(design, population, supporting numbers)
Summary · context
A total of 32 healthy participants were randomized to receive either EXE once weekly (2 mg/wk subcutaneously; six men, 10 women, mean age 59.9 ± 0.9 years, mean body mass index [BMI] 29.6 ± 0.6 kg/m² ) or matching placebo (PBO; six men, 10 women, mean age 60.6 ± 1.2 years, mean BMI 29.5 ±…
Report a problemFND-3190371208

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.